Deciphering the Signaling Mechanisms of Osteosarcoma Tumorigenesis
International Journal of Molecular Sciences · 12.07.2023 · 24 (14) · 11367
DOI: 10.3390/ijms241411367 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 12.07.2023. Verfasst von Bikesh K Nirala und 2 weiteren Autor:innen. Beteiligte Einrichtung: Aflac Cancer and Blood Disorders Center, Emory University, Atlanta, GA 30322, USA. Hauptthemen laut MEDLINE: Osteosarcoma, Bone Neoplasms. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 135 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIBIB NIH HHS, NCI NIH HHS, National Institute of Health.
Abstract (Originalsprache)
Osteosarcoma (OS) is the predominant primary bone tumor in the pediatric and adolescent populations. It has high metastatic potential, with the lungs being the most common site of metastasis. In contrast to many other sarcomas, OS lacks conserved translocations or genetic mutations; instead, it has heterogeneous abnormalities, including somatic DNA copy number alteration, ploidy, chromosomal amplification, and chromosomal loss and gain. Unfortunately, clinical outcomes have not significantly improved in over 30 years. Currently, no effective molecularly targeted therapies are available for this disease. Several genomic studies showed inactivation in the tumor suppressor genes, including p53, RB, and ATRX, and hyperactivation of the tumor promoter genes, including MYC and MDM2, in OS. Alterations in the major signaling pathways, including the PI3K/AKT/mTOR, JAK/STAT, Wnt/β-catenin, NOTCH, Hedgehog/Gli, TGF-β, RTKs, RANK/RANKL, and NF-κB signaling pathways, have been identified in OS development and metastasis. Although OS treatment is currently based on surgical excision and systematic multiagent therapies, several potential targeted therapies are in development. This review focuses on the major signaling pathways of OS, and we propose a biological rationale to consider novel and targeted therapies in the future.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Aflac Cancer and Blood Disorders Center, Emory University, Atlanta, GA 30322, USA.
ORCID-Profile: Jason T Yustein
Förderung
- NIBIB NIH HHS
- NCI NIH HHS
- National Institute of Health
- Osteosarcoma Institute
Zitieren
APA
Nirala, B. K., Yamamichi, T., & Yustein, J. T. (2023). Deciphering the Signaling Mechanisms of Osteosarcoma Tumorigenesis. International Journal of Molecular Sciences, 24(14), 11367. https://doi.org/10.3390/ijms241411367
Vancouver
Nirala BK, Yamamichi T, Yustein JT. Deciphering the Signaling Mechanisms of Osteosarcoma Tumorigenesis. International Journal of Molecular Sciences. 2023;24(14):11367. doi:10.3390/ijms241411367
BibTeX
@article{Nirala2023,
author = {Nirala, Bikesh K and Yamamichi, Taku and Yustein, Jason T},
title = {Deciphering the Signaling Mechanisms of Osteosarcoma Tumorigenesis},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {14},
pages = {11367},
doi = {10.3390/ijms241411367}
}
EUVIMED